IUGNF - Imugene opens enrolment for Bile Tract Cancer expansion study

(NewsDirect)

Imugene Ltd (ASX:IMU) CEO Leslie Chong sits down with Proactive’sJonathan Jackson to discuss enrolment for a pivotal expansion studytargeting bile tract cancer (cholangiocarcinoma) patients. Thisfollows the successful completion of the fifth high-dose cohort in theintratumoural arm of the VAXINIA monotherapy dose escalation study,which evaluates the effectiveness of the cancer-killing virusCF33-hNIS (VAXINIA).Chong gives insight into the new phase of thestudy, particularly given VAXINIA's promising results ingastrointestinal cancers. Notably, the trial has already seenremarkable outcomes, including one patient with cholangiocarcinomaachieving a complete response and another maintaining stabledisease.The expansion trial, known as the MAST trial, aims to enrol 10patients and is part of Imugene’s broader efforts to advance itsinnovative oncological treatments. Previous phases have demonstratedsignificant positive responses, especially in gastrointestinalcancers, further underscoring the potential of VAXINIA.Additionally,this week, Imugene will present VAXINIA at the 2024 CholangiocarcinomaFoundation Annual Conference. The company continues to gather supportfor its cutting-edge therapies, which have so far shown no safetyconcerns across various cancer types, including thymic carcinoma andtriple-negative breast cancer.

ContactDetails

Proactive Investors

JonathanJackson

+61 413 713 744

jonathan@proactiveinvestors.com

Copyright (c) 2024 TheNewswire - All rights reserved.